Morphic Holding, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-08-16: Form 8-K; Period of report 2024-08-16; Description 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.02.
- 2024-07-08: Form 8-K; Period of report 2024-07-07; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2024-06-05: Form 8-K; Period of report 2024-06-04; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2024-04-26: Form 8-K; Period of report 2024-04-25; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2024-08-16 | 8-K | 2024-08-16 | 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.02 On August 16, 2024, in connection with the consummation of the Merger and effective as of the Effective Time, (i) the Company terminated the Company’s 2018 Stock Incentive Plan, Amended and Restated 2019 Equity Incentive Plan, 2019 Employee Stock Purchase Plan and 2024 Equity Inducement Plan and (ii) the Investors’ Rights Agreement entered into as of December 5, 2018, by and among the Company and the investors listed on Schedule A thereto, terminated automatically in accordance with its terms. 2.01 The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. 3.01 On August 16, 2024, the Company (i) notified The Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq suspend trading of the Common Stock, effective as of close of business on August 16, 2024, and file with the SEC a Form 25, Notification of Removal from Listing and/or Registration, to delist all the Common Stock from Nasdaq and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 3.03 The information set forth in the Introductory Note and Items 2.01, 3.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.01 The information contained in the Introductory Note and Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.02 The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated herein by reference. 5.03 Pursuant to the terms of the Merger Agreement, the restated certificate of incorporation of the Company was amended and restated in its entirety, effective as of the Effective Time, and the bylaws of the Purchaser became the bylaws of the Company, effective as of immediately following the Effective Time. | d877674d8k.htm |
| 2024-07-08 | 8-K | 2024-07-07 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On July 8, 2024, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. | d791725d8k.htm |
| 2024-06-05 | 8-K | 2024-06-04 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 4, 2024, Morphic Holding, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which the matters listed below were submitted to a vote of the Company’s stockholders. | morf-20240604.htm |
| 2024-04-26 | 8-K | 2024-04-25 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 On April 26, 2024, Morphic Holding, Inc., a Delaware corporation (the “Company” or “Morphic”), entered into a Sales Agreement (the “TD Cowen Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $350,000,000 (the “TD Cowen ATM Shares”), through TD Cowen as sales agent pursuant to an at-the-market offering program (the “TD Cowen ATM Program”). 1.02 As previously disclosed, in July 2020, the Company entered into an Open Market Sale AgreementSM (as amended by Amendment No. 1 to the Open Market Sale AgreementSM, the “Prior Agreement”) with Jefferies LLC (“Jefferies”) under which the Company could offer and sell, from time to time at its sole discretion, shares of Common Stock having an aggregate offering amount of up to $150,000,000 through Jefferies as sales agent. | morf-20240425.htm |
| 2024-04-25 | 8-K | 2024-04-25 | 2.02 Results of Operations and Financial Condition | 2.02 On April 25, 2024, Morphic Holding, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. | morf-20240425.htm |
| 2024-03-12 | 8-K | 2024-03-12 | 7.01 Regulation FD Disclosure | 7.01 On March 12, 2024, the Company updated its corporate presentation. | morf-20240312.htm |
| 2024-02-22 | 8-K | 2024-02-22 | 2.02 Results of Operations and Financial Condition | 2.02 On February 22, 2024, Morphic Holding, Inc. issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023. | morf-20240222.htm |
| 2024-01-12 | 8-K | 2024-01-10 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 10, 2024, Morphic Holding, Inc. (the “Company”) announced in a Q&A session during a public presentation that as of December 31, 2023, it had preliminary cash, cash equivalents and marketable securities totaling approximately $700 million. 7.01 On January 10, 2024, the Company updated its corporate presentation. | tm243182d1_8k.htm |
| 2024-01-03 | 8-K | 2024-01-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 3, 2024, Morphic Holding, Inc. (the “Company”) announced that Praveen Tipirneni, M.D., the Company’s Chief Executive Officer, has returned to work from his temporary medical leave of absence. | morf-20240102.htm |
| 2023-12-06 | 8-K | 2023-12-01 | 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics | 5.05 On December 1, 2023, the Board of Directors (the “Board”) of Morphic Holding, Inc., a Delaware corporation (the “Company”), approved certain amendments to its Code of Conduct and Ethics (as amended, the “Code”). | morf-20231201.htm |
| 2023-11-03 | 8-K | 2023-11-01 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 3, 2023, Morphic Holding, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2023. 5.02 As previously announced on September 26, 2023, Praveen P. Tipirneni, M.D., the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), is taking a temporary medical leave of absence from his role as Chief Executive Officer. | morf-20231101.htm |
| 2023-10-12 | 8-K | 2023-10-12 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On October 12, 2023, Morphic Holding, Inc. (the “Company”) announced that as of September 30, 2023, it had preliminary cash, cash equivalents and marketable securities totaling approximately $725 million. 8.01 On October 12, 2023, the Company presented additional data from its EMERALD-1 open-label, single-arm Phase 2a trial of MORF-057 at a dose of 100 mg twice daily in patients with moderate to severe ulcerative colitis. | morf-20231012.htm |
| 2023-09-26 | 8-K | 2023-09-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Morphic Holding, Inc. (“Morphic” or “our”) announces that Praveen Tipirneni, M.D., our Chief Executive Officer, experienced an unexpected medical event, is actively recovering, and is taking a temporary medical leave of absence. | morf-20230926.htm |
| 2023-08-03 | 8-K | 2023-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2023, Morphic Holding, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2023. | morf-20230803.htm |
| 2023-06-02 | 8-K | 2023-06-01 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 1, 2023, Morphic Holding, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which the matters listed below were submitted to a vote of the Company’s stockholders. | morf-20230601.htm |
| 2023-05-03 | 8-K | 2023-05-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On May 2, 2023, Morphic Holding, Inc. (“Morphic”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which Morphic agreed to issue and sell 5,333,334 shares of its common stock (the “Shares”) to the Underwriters (the “Offering”). 8.01 On May 2, 2023 and May 3, 2023, Morphic issued press releases announcing the launch and the pricing of the Offering, respectively. | tm2314474d1_8k.htm |
| 2023-04-25 | 8-K | 2023-04-25 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On April 25, 2023, Morphic Holding, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2023. 8.01 On April 25, 2023, the Company issued a press release announcing positive topline results from the main cohort (n=35) of the EMERALD-1 open-label, single-arm Phase 2a trial of MORF-057 at dose of 100 mg twice daily in patients with moderate to severe ulcerative colitis. | morf-20230425.htm |
| 2023-04-25 | 8-K | 2023-04-25 | 8.01 Other Events | 8.01 On April 25, 2023, Morphic Holding, Inc. (the “Company”) presented data from the main cohort (n=35) of the EMERALD-1 open-label, single-arm Phase 2a trial of MORF-057 at a dose of 100 mg twice daily in patients with moderate to severe ulcerative colitis. | tm2313636d1_8k.htm |
| 2023-02-23 | 8-K | 2023-02-23 | 2.02 Results of Operations and Financial Condition | 2.02 On February 23, 2023, Morphic Holding, Inc. (the Company”) issued a press release (the “Press Release”) announcing its preliminary financial results for the year ended December 31, 2022. | morf-20230223.htm |
| 2023-02-13 | 8-K | 2023-02-12 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 On February 13, 2023, Morphic Holding, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors listed on the signature pages thereto (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 848,655 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $35.35 per share and (ii) 1,980,198 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,980,198 shares of Common Stock (the “Warrant Shares” and, together with the Shares and the Pre-Funded Warrants, the “Securities”) at a purchase price of $35.3499 per Pre-Funded Warrant. 3.02 The information contained above under Item 1.01, to the extent required by Item 3.02 of Form 8-K, is hereby incorporated by reference herein. 5.03 On February 12, 2023, in connection with the effectiveness of new SEC rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of the Company, the Company’s board of directors (the “Board”) approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective. | tm236505d1_8k.htm |
| 2023-01-20 | 8-K | 2023-01-13 | 1.02 Termination of a Material Definitive Agreement | 1.02 On January 13, 2023, Morphic Holding, Inc. (the “Company”) received notice from Janssen Pharmaceuticals, Inc. (“Janssen”) that Janssen has elected to terminate the Research Collaboration and Option Agreement between Janssen and Morphic Therapeutic, Inc., a wholly owned subsidiary of the Company (“Morphic”), dated February 15, 2019 (as amended by Amendment No. 1 to the Research Collaboration and Option Agreement between Morphic and Janssen, dated as of December 30, 2020, and as further expanded and amended to include research to develop antibody activators for an undisclosed integrin target by Amendment No. 2 to the Research Collaboration and Option Agreement between Morphic and Janssen, dated as of June 18, 2021, the “Collaboration Agreement”). | morf-20230113.htm |
| 2022-11-02 | 8-K | 2022-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2022, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended September 30, 2022. | morf-20221102.htm |
| 2022-10-24 | 8-K | 2022-10-24 | 8.01 Other Events | 8.01 On October 24, 2022, Morphic Holding, Inc. (the “Company”) issued a press release announcing the completion of targeted enrollment of the main cohort and ongoing enrollment of an exploratory cohort of patients who have previously failed treatment with vedolizumab in the EMERALD-1 clinical trial (MORF-057-201), which is an open-label multi-center Phase 2a trial designed to evaluate the efficacy, safety and tolerability of MORF-057 in adults with moderate to severe ulcerative colitis (“UC”) in the United States and Poland. | morf-20221024.htm |
| 2022-08-03 | 8-K | 2022-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2022, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended June 30, 2022. | morf-20220803.htm |
| 2022-06-21 | 8-K | 2022-06-16 | 1.02 Termination of a Material Definitive Agreement | 1.02 On June 16, 2022, Morphic Holding, Inc. (the “Company”) received notice from AbbVie Biotechnology Ltd (“AbbVie”) that AbbVie has elected to terminate the Collaboration and Option Agreement (the “Collaboration Agreement”) between AbbVie and Morphic Therapeutic, Inc., a wholly owned subsidiary of the Company (“Morphic”), dated October 16, 2018. | morf-20220616.htm |
| 2022-06-09 | 8-K | 2022-06-08 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 8, 2022, Morphic Holding, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”), at which the matters listed below were submitted to a vote of the Company’s stockholders. | morf-20220608.htm |
| 2022-05-12 | 8-K | 2022-05-11 | 5.01 Changes in Control of Registrant; 7.01 Regulation FD Disclosure | 7.01 The Company announced the appointment of Dr. Rogers to the position of President of the Company and the appointment of Dr. Lippa to the position of CSO of the Company in a press release furnished as Exhibit 99.1. | morf-20220511.htm |
| 2022-05-04 | 8-K | 2022-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2022, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended March 31, 2022. | morf-20220504.htm |
| 2022-03-15 | 8-K | 2022-03-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 14, 2022, Dr. Martin Edwards resigned as a Class II director of Morphic Holding, Inc. (the “Company”) and the board of directors of the Company (the “Board”) immediately reappointed Mr. Edwards as a Class III director in order to achieve an equal apportionment of membership among the Board’s three classes of directors. | morf-20220315.htm |
| 2022-02-24 | 8-K | 2022-02-24 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On February 24, 2022, Morphic Holding, Inc. (the Company”) issued a press release (the “Press Release”) announcing its preliminary financial results for the year ended December 31, 2021. 5.02 Resignation of Directors for Any Reason Other than Disagreement with the Company. | morf-20220224.htm |
| 2021-11-04 | 8-K | 2021-11-02 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On November 4, 2021, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended September 30, 2021. 5.02 On November 2, 2021, Peter G. Linde M.D. notified the Company of his resignation effective 12/31/2021. | morf-20211102.htm |
| 2021-08-23 | 8-K | 2021-08-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective on August 19, 2021, the Board of Directors (the “Board”) of Morphic Holding, Inc. (the “Company”) appointed Dr. Nisha Nanda to serve on the Board as a Class III Director. 8.01 The Company announced the election of Dr. Nanda by the Company’s Board in a Press Release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference. | morf-20210819.htm |
| 2021-08-04 | 8-K | 2021-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2021, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended June 30, 2021. | morf-202185x8k1.htm |
| 2021-07-09 | 8-K | 2021-07-09 | 8.01 Other Events | 8.01 On July 9, 2021, Morphic Holding, Inc. (“Morphic”) announced positive topline results from its Phase 1 clinical trial for MORF-057 which were presented at the Congress of European Crohn’s and Colitis Organization (ECCO) 2021 Virtual Congress on July 9, 2021. | morphic-8xkxecco.htm |
| 2021-06-21 | 8-K | 2021-06-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 16, 2021, Morphic Holding, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders. | morphic-2021annualshmeetin.htm |
| 2021-06-01 | 8-K | 2021-05-28 | 8.01 Other Events | 8.01 On May 28, 2021, Morphic Holding, Inc. (“Morphic”) announced that the new Phase 1 data for MORF-057 will be presented in an ePoster at the Congress of European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress on July 9, 2021. | tm2118181d1_8k.htm |
| 2021-04-29 | 8-K | 2021-04-29 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.02 On April 29, 2021, the Company issued a press release (the “Press Release”) announcing its preliminary financial results for the quarter ended March 31, 2021. 5.02 Effective on April 27, 2021, the Board of Directors (the “Board”) of Morphic Holding, Inc. (the “Company”) appointed Susannah Gray to serve on the Board as a Class II Director. 8.01 The Company announced the election of Ms. Gray to the Company’s Board, Dr. Stampacchia’s resignation and Mr. Goyal’s determination not to stand for reelection, in a Press Release furnished as Exhibit 99.2 to this report and is incorporated herein by this reference. | morf-2021429x8k.htm |
| 2021-03-03 | 8-K | 2021-03-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On March 2, 2021, Morphic Holding, Inc. (“Morphic”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which Morphic agreed to issue and sell 3,500,000 shares of its common stock (the “Shares”) to the Underwriters (the “Offering”). 8.01 On March 2, 2021, Morphic issued a press release announcing the pricing of the Offering. | tm218034d5_8k.htm |
| 2021-03-01 | 8-K | 2021-03-01 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On March 1, 2021, Morphic Holding, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2020. 8.01 On March 1, 2021, the Company issued a press release announcing positive interim results from its single ascending dose (“SAD”) Phase 1 clinical trial of MORF-057. | tmb-20210301x8k.htm |
| 2021-01-05 | 8-K | 2021-01-05 | 8.01 Other Events | 8.01 On January 5, 2021, Morphic Holding, Inc. (“Morphic”) announced the expansion of its research and development collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. | tm2039530d1_8k.htm |
| 2020-12-04 | 8-K | 2020-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective on December 1, 2020, the Board of Directors (the “Board”) of Morphic Holding, Inc. (the “Company”) increased the authorized number of directors on the Board from nine (9) to ten (10) and appointed Martin Edwards to serve on the Board as a Class II Director. 8.01 The Company announced the election of Dr. Edwards to the Company’s Board of Directors in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference. | tm2037657d1_8k.htm |
| 2020-11-09 | 8-K | 2020-11-09 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 9, 2020, Morphic Holding, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. 7.01 On November 6, 2020, Alexey A. Lugovskoy, Ph.D., the Chief Development Officer of the Company, notified the Company that he intends to resign, effective November 20, 2020. | tmb-20201109x8k.htm |
| 2020-09-23 | 8-K | 2020-09-23 | 8.01 Other Events | 8.01 Morphic Holding, Inc. presented the investor presentation attached hereto as Exhibit 99.1 at the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020. | tm2031568-1_8k.htm |
| 2020-08-25 | 8-K | 2020-08-25 | 8.01 Other Events | 8.01 On August 25, 2020, Morphic Holding, Inc. (“Morphic”) announced that AbbVie Inc. (“AbbVie”) has exercised its license option under the companies’ existing research and development collaboration agreement (the “AbbVie Agreement”) to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis and additional indications. | tm2029340-1_8k.htm |
| 2020-08-10 | 8-K | 2020-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2020, Morphic Holding, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2020. | tmb-20200810x8k.htm |
| 2020-06-19 | 8-K | 2020-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 18, 2020, Morphic Holding, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders. | tm2022812d1_8k.htm |
| 2020-05-06 | 8-K | 2020-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2020, Morphic Holding, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020. | tmb-20200506x8k.htm |
| 2020-04-07 | 8-K | 2020-04-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 7, 2020, Morphic Holding, Inc., (the “Company”) announced that it appointed Marc Schegerin as the Chief Financial Officer of the Company, including as the “principal financial officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, pursuant to an offer letter dated February 3, 2020 (the “Offer Letter”). | tm2015224d1_8k.htm |
| 2020-03-30 | 8-K | 2020-03-26 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 26, 2020, the Board of Directors (the “Board”) of Morphic Holding, Inc. (the “Company”) amended the Company’s Restated Bylaws (the “Bylaws Amendment”) to adopt a new Article XI: Exclusive Forum, a provision designating the federal district courts of the United States as the exclusive jurisdiction for any litigation arising under the Securities Act of 1933, as amended. | tm2014002d1_8k.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 8.01 Other Events | 8.01 Morphic Holding, Inc. presented the investor presentation attached hereto as Exhibit 99.1 at the Cowen Healthcare Conference on March 4, 2020. | tm2011644-1_8k.htm |
| 2020-02-27 | 8-K | 2020-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2020, Morphic Holding, Inc. issued a press release announcing its financial results for the year ended December 31, 2019. | f8-k.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 7.01 Regulation FD Disclosure | 7.01 Morphic Holding, Inc. plans to present the investor presentation attached hereto as Exhibit 99.1 at the J.P. Morgan Healthcare Conference on January 15, 2020, and is filing its strategic deck, which will be used in meetings, attached hereto as Exhibit 99.2. | tm202189d1_8k.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, Morphic Holding, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. | f8-k.htm |
| 2019-08-12 | 8-K | 2019-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2019, Morphic Holding, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2019. | a19-16958_18k.htm |